|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 6,716,416: Scope, Claims, and Landscape
United States Patent 6,716,416, titled "Novel crystalline forms of Olanzapine," issued to Eli Lilly and Company on April 4, 2002. The patent claims specific crystalline forms of olanzapine, an atypical antipsychotic used to treat schizophrenia and bipolar disorder. This analysis details the patent's scope, key claims, and relevant aspects of the patent landscape.
What is the Primary Invention Covered by US Patent 6,716,416?
The patent’s core invention is the identification and characterization of specific crystalline forms, or polymorphs, of olanzapine. These forms possess distinct physical and chemical properties compared to other known crystalline structures of the active pharmaceutical ingredient (API). Specifically, the patent focuses on crystalline forms designated as Form I and Form II of olanzapine, which are claimed to exhibit improved properties.
What Specific Claims Does US Patent 6,716,416 Encompass?
The patent contains multiple claims defining the scope of the invention. The most critical claims are:
- Claim 1: A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having significant peaks at approximately 20.3, 16.7, 13.0, 11.4, and 10.3 degrees 2-theta. This claim defines a specific crystalline form of olanzapine based on its X-ray diffraction (XRD) profile.
- Claim 2: A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having significant peaks at approximately 21.5, 18.6, 17.8, 13.7, and 12.8 degrees 2-theta. This claim defines another distinct crystalline form of olanzapine based on its XRD profile.
- Claim 3: A crystalline form of olanzapine according to claim 1, wherein said form is substantially free of other crystalline forms of olanzapine. This claim refines Claim 1 by requiring a high degree of purity for the specified crystalline form, distinguishing it from mixtures of polymorphs.
- Claim 4: A crystalline form of olanzapine according to claim 2, wherein said form is substantially free of other crystalline forms of olanzapine. Similar to Claim 3, this claim refines Claim 2 for purity.
- Claim 5: A process for preparing a crystalline form of olanzapine, comprising the step of crystallizing olanzapine from a solvent system comprising methanol and water. This claim protects a specific method for producing the claimed crystalline forms.
- Claim 6: A process for preparing a crystalline form of olanzapine, comprising the step of crystallizing olanzapine from a solvent system comprising isopropanol and water. This claim covers an alternative process for producing the claimed forms.
- Claim 7: A pharmaceutical composition comprising a crystalline form of olanzapine as claimed in claim 1 and a pharmaceutically acceptable carrier. This claim extends protection to a drug product formulation containing the specific crystalline form.
- Claim 8: A pharmaceutical composition comprising a crystalline form of olanzapine as claimed in claim 2 and a pharmaceutically acceptable carrier. This claim covers a formulation with the second claimed crystalline form.
These claims collectively aim to protect the specific solid-state forms of olanzapine and methods of their preparation and use in pharmaceutical formulations.
What is the Exclusivity Period for US Patent 6,716,416?
United States drug patents are typically granted for a term of 20 years from the filing date. US Patent 6,716,416 was filed on January 29, 2001, and issued on April 4, 2002. Therefore, its initial term of exclusivity would have expired on January 29, 2021.
It is important to note that patent term extensions (PTE) or adjustments may have been sought and granted for this patent, potentially extending the exclusivity period beyond the initial 20 years. These extensions are typically granted to compensate for delays in regulatory review by the U.S. Food and Drug Administration (FDA). For definitive information on the current status and any extensions, a thorough patent prosecution history review would be necessary.
What is the Status of US Patent 6,716,416 in the Patent Landscape?
The status of US Patent 6,716,416 is expired. As of April 4, 2022, the patent has reached its statutory 20-year term from the grant date. This means that the claims of the patent are no longer enforceable.
This expiration opens the door for generic manufacturers to produce and market olanzapine formulations using any crystalline form, including those previously protected by this patent, provided they do not infringe on other valid patents.
What are the Key Implications of Patent 6,716,416 for Generic Drug Development?
The expiration of US Patent 6,716,416 has significant implications for generic drug manufacturers:
- Freedom to Operate: Generic companies are now able to utilize the specific crystalline forms of olanzapine claimed in this patent without fear of infringement. This is particularly relevant if these forms offer manufacturing advantages or are the basis for existing branded drug formulations.
- Formulation Strategies: Generic developers can leverage the knowledge and specific crystalline forms disclosed in this expired patent when developing their own formulations. This could streamline the development process and potentially lead to bioequivalent products.
- Market Competition: The expiration of key patents on the API and its crystalline forms is a primary driver for increased competition in the olanzapine market. This typically leads to lower drug prices.
However, it is crucial to recognize that olanzapine may be protected by other patents, such as:
- Composition of Matter Patents: Patents claiming the olanzapine molecule itself. The original composition of matter patent for olanzapine has long since expired.
- Formulation Patents: Patents covering specific drug delivery systems, excipient combinations, or manufacturing processes for olanzapine formulations.
- Method of Use Patents: Patents claiming specific therapeutic uses of olanzapine that may not have expired.
Generic manufacturers must conduct a comprehensive freedom-to-operate analysis to ensure they do not infringe on any active and enforceable patents related to olanzapine.
What is the Relationship Between Patent 6,716,416 and Other Olanzapine Patents?
US Patent 6,716,416 is one of several patents that have protected Olanzapine (marketed as Zyprexa by Eli Lilly and Company). Its primary role was to secure intellectual property rights over specific crystalline forms of the active pharmaceutical ingredient. This is a common strategy in the pharmaceutical industry to extend market exclusivity beyond the original composition of matter patent.
For example, earlier patents would have claimed the olanzapine molecule itself. Subsequent patents, like 6,716,416, often focus on:
- Polymorphs: Different solid-state forms of the API, which can impact solubility, stability, and manufacturability.
- Salt Forms: Crystalline salts of the API, which can also alter physicochemical properties.
- Formulations: Specific combinations of the API with excipients to create a stable and effective dosage form.
- Manufacturing Processes: Novel and efficient methods for synthesizing the API or preparing its formulations.
- Methods of Treatment: New therapeutic indications or patient populations for which the drug is effective.
The expiration of patent 6,716,416 means that the protection it offered on specific crystalline forms has ended. However, the overall olanzapine market was, and may still be, influenced by other patents in force at various times. A complete understanding requires reviewing the patent portfolios for olanzapine from its initial development through to the present.
Has US Patent 6,716,416 Been Involved in Litigation?
Information regarding litigation specifically challenging or enforcing US Patent 6,716,416 is not readily available through standard patent databases without an in-depth legal case search. Many patent disputes, particularly concerning pharmaceutical patents, are settled out of court or occur as part of broader litigation involving multiple patents for a single drug.
If litigation did occur, it would likely have focused on:
- Infringement: Whether generic products utilized the crystalline forms claimed in the patent.
- Validity: Challenges to the patent's novelty, obviousness, or enablement based on prior art.
The expiration of the patent significantly reduces the likelihood of current litigation directly concerning its claims. However, disputes related to patent thickets and the exclusivity of pharmaceutical products are common.
What are the Key Takeaways?
- US Patent 6,716,416 protected specific crystalline forms (polymorphs) of olanzapine, identified as Form I and Form II, based on their X-ray diffraction patterns.
- The patent also claimed processes for preparing these crystalline forms and pharmaceutical compositions containing them.
- The patent's initial term expired on April 4, 2022, 20 years from its grant date, making its claims unenforceable.
- The expiration of this patent removes a significant barrier for generic manufacturers, allowing them to utilize these specific crystalline forms.
- Generic olanzapine development is subject to navigating other potentially active patents, including those covering formulations, methods of use, or other proprietary aspects.
Frequently Asked Questions
-
Does the expiration of Patent 6,716,416 mean all olanzapine is now off-patent?
No. Patent 6,716,416 specifically protected certain crystalline forms. The original patent covering the olanzapine molecule itself expired much earlier. However, other patents may still exist for specific formulations, manufacturing processes, or methods of use that could impact generic market entry.
-
What is a crystalline form (polymorph) in the context of a drug patent?
A crystalline form, or polymorph, refers to a specific arrangement of molecules in a solid-state drug substance. Different polymorphs of the same molecule can have varying physical properties such as solubility, dissolution rate, stability, and manufacturing characteristics, which can impact the drug's performance and patentability.
-
Can generic manufacturers freely use the crystalline forms claimed in Patent 6,716,416 now that it has expired?
Yes, once a patent expires, the public is generally free to use the invention claimed therein without licensing. This means generic manufacturers can now develop and market olanzapine using the specific crystalline forms defined by Patent 6,716,416, provided they do not infringe any other valid and enforceable patents.
-
How do patent term extensions (PTE) affect the expiry date of a patent like 6,716,416?
Patent term extensions are granted by regulatory bodies to compensate patent holders for market exclusivity lost during the FDA's regulatory review process. If a PTE was granted for US Patent 6,716,416, its effective expiration date would have been extended beyond the standard 20-year term from the filing date. The analysis presented here is based on the statutory term from the grant date; a definitive assessment of the actual market exclusivity would require examining the patent's prosecution history for any granted PTE.
-
What is the significance of X-ray diffraction (XRD) in defining a crystalline form in this patent?
X-ray diffraction is a technique used to determine the crystalline structure of a material. The specific angles (2-theta values) at which X-rays are diffracted by a crystalline solid are unique to its crystal lattice. By characterizing a crystalline form through its distinctive XRD pattern, inventors can precisely define and distinguish it from other potential crystalline structures of the same compound, thereby establishing patentable subject matter.
Citations
[1] Eli Lilly and Company. (2002). U.S. Patent 6,716,416: Novel crystalline forms of Olanzapine. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
